Franklin Biotechnology Discovery Fund Class R6
FRBRX
NASDAQ
| Weiss Ratings | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Company Info | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | Franklin Templeton | |||
| Manager/Tenure (Years) | Evan S. McCulloch (29), Akiva Felt (6) | |||
| Website | http://www.franklintempleton.com | |||
| Fund Information | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | Franklin Biotechnology Discovery Fund Class R6 | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Health | |||
| Inception Date | May 01, 2013 | |||
| Open/Closed To New Investors | Closed | |||
| Minimum Initial Investment | 1,000,000.00 | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 1.86% | |||
| Dividend | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.37% | |||
| Asset Allocation | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 1.55% | |||
| Stock | 97.25% | |||
| U.S. Stock | 90.42% | |||
| Non-U.S. Stock | 6.83% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 0.99% | |||
| Convertible | 0.00% | |||
| Other Net | 0.21% | |||
| Price History | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.11% | |||
| 30-Day Total Return | 1.94% | |||
| 60-Day Total Return | -9.91% | |||
| 90-Day Total Return | -7.05% | |||
| Year to Date Total Return | 12.18% | |||
| 1-Year Total Return | 26.71% | |||
| 2-Year Total Return | 55.20% | |||
| 3-Year Total Return | 111.60% | |||
| 5-Year Total Return | 67.92% | |||
| Price | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | -- | |||
| 1-Month High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price | -- | |||
| 52-Week High Price (Date) | -- | |||
| NAV | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $201.33 | |||
| 1-Month Low NAV | $185.11 | |||
| 1-Month High NAV | $201.33 | |||
| 52-Week Low NAV | $173.67 | |||
| 52-Week Low NAV (Date) | Mar 30, 2026 | |||
| 52-Week High NAV | $231.92 | |||
| 52-Week High Price (Date) | Aug 19, 2026 | |||
| Beta / Standard Deviation | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.64 | |||
| Standard Deviation | 20.91 | |||
| Balance Sheet | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 1.11B | |||
| Operating Ratios | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 0.67% | |||
| Turnover Ratio | 37.62% | |||
| Performance | FRBRX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 63.63% | |||
| Last Bear Market Total Return | -11.72% | |||